Clinical decision making in MOG antibody-associated disease

摘要

With the development of sensitive and specific cell-based assays, the detection of IgG antibodies targeting conformationally preserved full-length human myelin-oligodendrocyte glycoprotein (MOG) has differentiated anti-MOG antibody-associated disease (MOGAD) from other demyelinating disorders. The distinction of MOGAD from aquaporin-4-associated neuromyelitis optica spectrum disorder (AQP4-NMOSD) and multiple sclerosis emphasises the divergent pathophysiological, clinical, therapeutic, and prognostic implications of these diseases. In The Lancet Neurology, Marignier and colleagues provide a Personal View on the immunology, pathology, clinical spectrum, and treatment of MOGAD, based on a workshop at the 2019 meeting of the European Committee for Treatment and Research in Multiple Sclerosis.